Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Sell
38
USNA Quote, Financials, Valuation and Earnings
Last price:
$30.70
Seasonality move
:
7.73%
Day range:
$30.23 - $30.95
52-week range:
$23.10 - $48.85
Dividend yield:
0%
P/E ratio:
16.79x
P/S ratio:
0.67x
P/B ratio:
1.07x
Volume:
287.2K
Avg. volume:
161.3K
1-year change:
-32.67%
Market cap:
$568.9M
Revenue:
$854.5M
EPS (TTM):
$1.82
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Usana Health Sciences has 99.67% upside to fair value with a price target of $61.00 per share.
USNA vs. S&P 500
-
Over the past 5 trading days, Usana Health Sciences has overperformed the S&P 500 by 2.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Usana Health Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Usana Health Sciences has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Usana Health Sciences reported revenues of $249.5M.
Earnings Growth
-
Usana Health Sciences earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Usana Health Sciences reported earnings per share of $0.49.
Enterprise value:
466.4M
EV / Invested capital:
0.77x
Price / LTM sales:
0.67x
EV / EBIT:
7.00x
EV / Revenue:
0.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
9.50x
Price / Operating cash flow:
11.89x
Enterprise value / EBITDA:
4.96x
Gross Profit (TTM):
$705.7M
Return On Assets:
5.08%
Net Income Margin (TTM):
3.97%
Return On Equity:
6.41%
Return On Invested Capital:
6.3%
Operating Margin:
6.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $974.1M | $900.5M | $876.2M | $227.8M | $249.5M | |
| Gross Profit | $783.1M | $729.2M | $705.7M | $184.7M | $197.1M | |
| Operating Income | $101.4M | $90.9M | $57.3M | $24.7M | $15.7M | |
| EBITDA | $125.1M | $121.6M | $94M | $32.2M | $27.4M | |
| Diluted EPS | $3.39 | $3.21 | $1.82 | $0.86 | $0.49 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $373.2M | $363.8M | $395.9M | $421.1M | $281.4M | |
| Total Assets | $584.5M | $572.9M | $605.5M | $629.3M | $746.6M | |
| Current Liabilities | $151.5M | $158M | $130.2M | $112.6M | $137.4M | |
| Total Liabilities | $181.7M | $183M | $150.2M | $129.3M | $162.7M | |
| Total Equity | $402.8M | $389.9M | $455.4M | $500M | $583.9M | |
| Total Debt | -- | $10M | -- | $1.3M | $23M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $97M | $75.5M | $58.8M | $17.7M | $15.5M | |
| Cash From Investing | -$14M | -$12.7M | -$212.9M | -$4.1M | -$3.9M | |
| Cash From Financing | -$13.7M | -$23M | $7M | -$11.9M | -$14.5M | |
| Free Cash Flow | $86.3M | $59.9M | $49.1M | $14.5M | $12.7M | |
USNA
Sector
Market Cap
$568.9M
$256M
Price % of 52-Week High
62.54%
74.38%
Dividend Yield
0%
0%
Shareholder Yield
1.55%
2.87%
1-Year Price Total Return
-32.87%
-10.24%
Beta (5-Year)
0.630
0.395
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$30.34
200-day SMA
Sell
Level
$33.17
Bollinger Bands (100)
Buy
Level
26.64 - 31.72
Chaikin Money Flow
Buy
Level
4.4M
20-day SMA
Buy
Level
$30.03
Relative Strength Index (RSI14)
Buy
Level
57.56
ADX Line
Buy
Level
26.8
Williams %R
Neutral
Level
-28.4464
50-day SMA
Buy
Level
$28.66
MACD (12, 26)
Buy
Level
0.41
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
13.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.1364)
Buy
CA Score
(Annual)
Level (1.648)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.1478)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Stock Forecast FAQ
In the current month, USNA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The USNA average analyst price target in the past 3 months is $61.00.
-
Where Will Usana Health Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Usana Health Sciences share price will rise to $61.00 per share over the next 12 months.
-
What Do Analysts Say About Usana Health Sciences?
Analysts are divided on their view about Usana Health Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Usana Health Sciences is a Sell and believe this share price will drop from its current level to $61.00.
-
What Is Usana Health Sciences's Price Target?
The price target for Usana Health Sciences over the next 1-year time period is forecast to be $61.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is USNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Usana Health Sciences is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of USNA?
You can purchase shares of Usana Health Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Usana Health Sciences shares.
-
What Is The Usana Health Sciences Share Price Today?
Usana Health Sciences was last trading at $30.70 per share. This represents the most recent stock quote for Usana Health Sciences. Yesterday, Usana Health Sciences closed at $30.71 per share.
-
How To Buy Usana Health Sciences Stock Online?
In order to purchase Usana Health Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Why Did Howard Marks Buy Grab Stock?
When a legendary value investor who cut his teeth in…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 42x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
59
NKTR alert for Jun 25
Nektar Therapeutics [NKTR] is up 24.25% over the past day.
Buy
58
AMBA alert for Jun 25
Ambarella [AMBA] is up 2.91% over the past day.
Buy
65
EXOD alert for Jun 25
Exodus Movement [EXOD] is down 9.22% over the past day.
